Dementia and Alzheimer Disease

Patients under the age of 65 were not shown to derive benefit from DBS, but researchers noted that this doesn’t mean it is not helpful for older patients.

Cannabinoids are being explored in a variety of conditions, ranging from Alzheimer disease to migraine.

Learn about the most insightful article Dr Lazzara has ever read in a research journal.

Neurology News Network for the week of Oct. 12, 2018.

The guidance provides clinicians with tools allowing for earlier and more accurate diagnosis of Alzheimer disease.

Although the history of developments in Alzheimer has been littered with failures, there remains reason to be hopeful about the future.

Almost 45% of those who received an antidementia treatment experienced the never event of co-administration of a high-potency anticholinergic medication and an acetylcholinesterase inhibitor.

Lanctôt advised ruling out any possible underlying medical conditions that could be causing it, including pain, as well as starting with any non-pharmacologic interventions.

Neurology News Network for the week of September 28, 2018.

Potential risk factors may identify those at risk for AD and similar disorders as early as adolescence.

The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University spoke about the beginnings of her work with efavirenz.

The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine shared his feelings on the early phase treatments.

Chylinski spoke about the relationship between the increased number of arousals during sleep and the pathogenesis of Alzheimer disease.

The Director of Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the importance of clarity in patient identification and assessment.

Fillit spoke about remaining need for additional biomarkers in Alzheimer, and what has been developed in recent years.

The psychiatry and pharmacology professor at the University of Toronto and senior scientist at Sunnybrook Research Institute spoke about the use of cannabinoids to treat agitation in Alzheimer.

The Director of Cleveland Clinic Lou Ruvo Center for Brain Health spoke about the rapidly changing landscape of treatments for Alzheimer disease.

The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University further discussed the trial of efavirenz in AD.

Neurology News Network for the week of September 22, 2018.

The accuracy and potential utility of the [18F]flortaucipir tracer in patient care will require further research in clinically more representative populations.

The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine explained more about the molecule and the subsequent trial of it.

With a heavy focus on the need for new treatments in Alzheimer, there remains a need to ensure patients are cared for first and foremost.

Novel biomarkers are being explored to help expedite the development of new treatments for Alzheimer disease.

Could the introduction of gene therapies into the Alzheimer space be the beginning of a new era of treatment?

The associate professor of neurology at Mayo Clinic spoke about targeting mitochondria to treat neurologic disorders.